Skip to main content
OpenTrials
Completed

NCT Number: NCT02991352

Stereotactic MRI Based Image Guidance for the Treatment of Vascular Malformations - a Pilot Study

Treatment of vascular malformations requires the placement of a needle within anatomically non well defined, pathological vessels, which may be as small as 1 mm, with the current state of the art relying exclusively on two dimensional fluoroscopy images for guidance. The investigators hypothesize that the combination of stereotactic image guidance with existing targeting methods will result in faster and more reproducible needle placements.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ARTORG Center for Biomedical Engineering, Bern, Switzerland

Loading trial locations.

About this study

This prospective study aims to investigate the feasibility of the utilization of stereotactic image guidance technology for the needle based percutaneous treatment of peripheral vascular malformations. The specific device to be utilized is the CAS-One IR system, CE marked for use with needle based procedures in combination with medical image data including MRI data, as required by this study.

Utilizing feedback from the stereotactic image guidance system, the interventionalist will attempt to place the needle within the malformation. The position and orientation of the needle relative to the anatomy will be displayed on 2D slices from the MRI, as well as relative to a 3D volume rendering of the patient anatomy constructed from MRI data. The position of the needle relative to the desired position within the malformation will be evaluated utilizing fluoroscopy.

If necessary the position of the needle will be adjusted, this adjustment can be performed utilizing navigated feedback or standard fluoroscopy feedback at the discretion of the physician. The final position of the needle will be confirmed on intra-operative DSA imaging and the sclerosant will be applied according to standard clinical protocols.

This single-centre pilot study will involve a total of 10 patients suffering from peripheral vascular malformations. Only non-emergency adult patients will be considered for inclusion in this trial. Inclusion will be at the discretion of the treating physician and patient. As the study is designed as a pilot trial, no comparator is considered and no blinding performed. The trial will be performed over a period of nine months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with venous or mixed venous-lymphatic malformation
  • Patients which are regular scheduled for a percutaneous treatment of a vascular malformation
  • Informed Consent as documented by signature

Exclusion criteria

  • Age < 18 years

Treatment and study plan

Image guided needle placement

Device

Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)

Primary outcomes

  1. Time to reach the target

    Time frame: During the intervention (duration approx. 90 minutes on average)

    Time from start of targeting to alcohol embolization in minutes

Secondary outcomes

  1. Radiation time

    Time frame: During the intervention (duration approx. 90 minutes on average)

    Measured by the C-arm imaging device in seconds

  2. Radiation dose

    Time frame: During the intervention (duration approx. 90 minutes on average)

    Measured by the C-arm imaging device in μGym²

  3. Contrast agent volume

    Time frame: During the intervention (duration approx. 90 minutes on average)

    Measured by the nurses in milliliter

  4. Number of attempts

    Time frame: During the intervention (duration approx. 90 minutes on average)

    Defined as number of skin punctures, counted by the investigator

  5. Reason to change to standard approach

    Time frame: During the intervention (duration approx. 90 minutes on average)

    Asked by the investigator

  6. System Usability Score (SUS)

    Time frame: Directly after the intervention (60 minutes afterwards at the latest)

    Filled out by the interventionalist

Sponsors and collaborators

Lead sponsor

Insel Gruppe AG, University Hospital Bern

Other

Collaborators

  • University of Bern

Registry information

Acronym: SIGVaM

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Dec 13, 2016
Registry last updated
Dec 15, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.